Kymera Therapeutics First Quarter 2025 Earnings: Beats Expectations

Kymera Therapeutics (NASDAQ:KYMR) First Quarter 2025 Results

Key Financial Results

• Revenue: US$22.1m (up 115% from 1Q 2024).
• Net loss: US$65.6m (loss widened by 35% from 1Q 2024).
• US$0.82 loss per share (further deteriorated from US$0.69 loss in 1Q 2024).

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Kymera Therapeutics Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 106%. Earnings per share (EPS) also surpassed analyst estimates by 8.9%.

Looking ahead, revenue is forecast to grow 42% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are down 15% from a week ago.

Risk Analysis

Don't forget that there may still be risks. For instance, we've identified 2 warning signs for Kymera Therapeutics that you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.